drug · protein
EYLEA HD
Marketedupdated 3mo agoby $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
Approvedannual revenue · 2024–2024peak $9.4B
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval44 co-mentions · 15 sources
- drugEylea32 co-mentions · 15 sources
- drugYESAFILI18 co-mentions · 7 sources
- drugaflibercept biosimilar17 co-mentions · 10 sources
- drugOPUVIZ8 co-mentions · 4 sources
- drugENZEEVU6 co-mentions · 3 sources
- companySamsung Bioepis Co Ltd4 co-mentions · 4 sources
- companyBiocon Biologics Ltd4 co-mentions · 2 sources
Protein drug with a maximum clinical stage of Approval (across all indications), with 16 approved and 39 investigational indications.
indications
investigational
Diabetic Macular Edema
targets
Placenta growth factorVascular endothelial growth factor A, long form
all catalysts(5)
approval · 5
Aug 18, 2023
approval
$REGN826.64-1.69%
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Dec 14, 2023
approval
$REGN826.64-1.69%
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Oct 10, 2024
approval
$REGN826.64-1.69%
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Nov 19, 2025
approval
$REGN826.64-1.69%
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Apr 2, 2026
approval
$REGN826.64-1.69%
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Trials studying EYLEA HD
- phase3A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
- phase3Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
- phase3A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
- phase3CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
- phase3COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
- phase2A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
- phase3A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
- phase3A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
News(10)
- Regeneron to challenge Ipsen as FDA clears bone disease drugPasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.biopharma_dive · 11h ago
- EyePoint’s bid to compete with Eylea falls flatEyePoint’s experimental eye treatment came up short of Eylea, the current go-to option for wet age-related macular degeneration, according to results of a Phase 3 trial. The company’s shares {$EYPT…endpoints · 3d ago
- EyePoint plummets on pivotal data for main drugThough its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.biopharma_dive · 3d ago
- EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD raceEyePoint’s quest to reduce treatment burden for patients with age-related macular degeneration has hit a bump in the road, with a clinical miss driving the biotech’s stock down by 70%.biospace · 3d ago
- Scholar Rock rejigs approval filing after FDA flags violations at Novo plantDespite earlier claims of improvement at the fill-finish plant, the FDA has classified the facility as Official Action Indicated based on inspection findings.biospace · 9d ago
- Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drugScholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a recent inspection of…fiercebiotech · 10d ago
- Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chestCalls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.biospace · 21d ago
- FDA scientists question Capricor data; Legend CEO steps downCapricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…biopharma_dive · 24d ago
- Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapiesRoche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told Fierce that still has a strategy for developing cell therapies for autoimmune disea…fiercebiotech · 28d ago
- ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadershipThe ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.biopharma_dive · 1mo ago
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that